Authors:
Braybrooke, JP
Propper, DJ
O'Byrne, KJ
Koukourakis, MI
Patterson, AV
Houlbrook, S
Love, SD
Varcoe, S
Taylor, M
Ganesan, TS
Talbot, DC
Harris, AL
Citation: Jp. Braybrooke et al., Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid andinterferon alpha, BR J CANC, 83(2), 2000, pp. 219-224
Authors:
Saunders, MP
Patterson, AV
Chinje, EC
Harris, AL
Stratford, IJ
Citation: Mp. Saunders et al., NADPH : cytochrome C (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line, BR J CANC, 82(3), 2000, pp. 651-656
Authors:
Saunders, MP
Jaffar, M
Patterson, AV
Nolan, J
Naylor, MA
Phillips, RM
Harris, AL
Stratford, IJ
Citation: Mp. Saunders et al., The relative importance of NADPH: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions, BIOCH PHARM, 59(8), 2000, pp. 993-996
Authors:
Chinje, EC
Patterson, AV
Saunders, MP
Lockyer, SD
Harris, AL
Stratford, IJ
Citation: Ec. Chinje et al., Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?, BR J CANC, 81(7), 1999, pp. 1127-1133
Citation: Av. Patterson et Ij. Stratford, Exploiting tumour-specific physiology to target redox-dependent molecular chemotherapy, EUROCANCER 98, 1998, pp. 285-287